Literature DB >> 18340341

The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease.

Aras Kadioglu1, Jeffrey N Weiser, James C Paton, Peter W Andrew.   

Abstract

Streptococcus pneumoniae is a Gram-positive bacterial pathogen that colonizes the mucosal surfaces of the host nasopharynx and upper airway. Through a combination of virulence-factor activity and an ability to evade the early components of the host immune response, this organism can spread from the upper respiratory tract to the sterile regions of the lower respiratory tract, which leads to pneumonia. In this Review, we describe how S. pneumoniae uses its armamentarium of virulence factors to colonize the upper and lower respiratory tracts of the host and cause disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18340341     DOI: 10.1038/nrmicro1871

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  452 in total

1.  Activator role of the pneumococcal Mga-like virulence transcriptional regulator.

Authors:  Virtu Solano-Collado; Manuel Espinosa; Alicia Bravo
Journal:  J Bacteriol       Date:  2012-06-01       Impact factor: 3.490

2.  Characterization of central carbon metabolism of Streptococcus pneumoniae by isotopologue profiling.

Authors:  Tobias Härtel; Eva Eylert; Christian Schulz; Lothar Petruschka; Philipp Gierok; Stephanie Grubmüller; Michael Lalk; Wolfgang Eisenreich; Sven Hammerschmidt
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

3.  Influenza virus induces bacterial and nonbacterial otitis media.

Authors:  Kirsty R Short; Dimitri A Diavatopoulos; Ruth Thornton; John Pedersen; Richard A Strugnell; Andrew K Wise; Patrick C Reading; Odilia L Wijburg
Journal:  J Infect Dis       Date:  2011-09-19       Impact factor: 5.226

4.  Analysis of invasiveness of pneumococcal serotypes and clones circulating in Portugal before widespread use of conjugate vaccines reveals heterogeneous behavior of clones expressing the same serotype.

Authors:  Raquel Sá-Leão; Francisco Pinto; Sandra Aguiar; Sónia Nunes; João A Carriço; Nelson Frazão; Natacha Gonçalves-Sousa; José Melo-Cristino; Hermínia de Lencastre; Mário Ramirez
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

Review 5.  Bacteraemic pneumococcal pneumonia: current therapeutic options.

Authors:  Charles Feldman; Ronald Anderson
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

6.  Interleukin-1β regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages.

Authors:  Helen M Marriott; Kate A Gascoyne; Ravi Gowda; Ian Geary; Martin J H Nicklin; Francesco Iannelli; Gianni Pozzi; Timothy J Mitchell; Moira K B Whyte; Ian Sabroe; David H Dockrell
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

7.  Serotype distribution and antimicrobial resistance of invasive pneumococcal disease strains in the Comunidad Valenciana, Spain, during the winter of 2009-2010: low PCV7 coverage and high levofloxacin resistance.

Authors:  C M Gant; A W Rosingh; J L López-Hontangas; M van der Heijden; F González-Morán; J J E Bijlsma; E Canton
Journal:  Antimicrob Agents Chemother       Date:  2012-07-02       Impact factor: 5.191

8.  Pneumolysin: stimulating protection.

Authors:  Sheilagh Molloy
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

9.  Molecular mechanisms driving Streptococcus mitis entry into human gingival fibroblasts in presence of chitlac-nAg and saliva.

Authors:  M Di Giulio; V Di Valerio; D Bosco; E Marsich; A Cataldi; L Cellini; S Sancilio
Journal:  J Mater Sci Mater Med       Date:  2018-03-19       Impact factor: 3.896

10.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.